

2023 National Preferred Formulary Exclusion List Changes

The excluded medications shown below are not covered on the Express Scripts National Preferred Formulary beginning July 1, 2023, unless otherwise noted. In most cases, if you fill a prescription for one of these drugs, you will pay the full retail price.

Single-Source Brand Exclusions

Drug Class	Excluded Medications	Preferred Alternatives
Cataplexy Treatment	XYREM	SODIUM OXYBATE, XYWAV
Central Nervous System Stimulants	METHYLPHENIDATE ER 45 MG & 63 MG*, METHYLPHENIDATE ER 72 MG, RELEXXII ER 45 MG & 63 MG*, RELEXXI ER 72 MG	dexmethylphenidate er, dextroamphetamine sulfate er, dextroamphetamine-amphetamine er, methylphenidate cd, methylphenidate er, methylphenidate la, DYANAVEL XR, MYDAYIS, QUILLICHEW ER, QUILLIVANT XR, VYVANSE
Metabolic Agents	RAVICTI	sodium phenylbutyrate, PHEBURANE
Ophthalmic Agents - Vascular Endothelial Growth Inhibitors	LUCENTIS	BYOOVIZ, CIMERLI
Pulmonary Anti-Inflammatory Inhalers	ALVESCO, ARMONAIR DIGIHALER*, FLOVENT DISKUS~, FLOVENT HFA~, FLUTICASONE PROPIONATE HFA*, PULMICORT FLEXHALER*	ARNUITY ELLIPTA, ASMANEX HFA, ASMANEX TWISTHALER, QVAR REDIHALER

Multi-Source Brand Exclusions

The generic equivalents of the following brand-name medications are covered on the National Preferred Formulary. FDA-approved generic medications meet strict standards and contain the same active ingredients as their corresponding brand-name medications, although they may have a different appearance.

APTENSIO XR

GILENYA

* Current 2023 exclusion in this class
~Exclusion impacts new starts only